Celsion
This article was originally published in The Gray Sheet
Executive Summary
Phase I safety investigational new drug application trial of firm's liposomal drug-delivery spheres for use with the Microfocus BPH 800 microwave urethroplasty system will commence following FDA clearance, firm says April 8 (1"The Gray Sheet" Oct. 26, 1998, p. 19). Study will examine heated liposome delivery of Pharmacia's Adriamycin (doxorubicin) in the treatment of prostate cancer. Technology was developed at Duke University and is licensed exclusively to Celsion...